PMID- 37057281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 14
IP  - 4
DP  - 2023
TI  - Inhibition of STAT3 signaling as critical molecular event in HUC-MSCs suppressed 
      Glioblastoma Cells.
PG  - 611-627
LID - 10.7150/jca.77905 [doi]
AB  - Objective: We investigated the effect of human umbilical cord mesenchymal stem 
      cells (HUC-MSCs) supernatants on proliferation, migration, invasion, and 
      apoptosis in glioblastoma (GBM) cell lines RG-2, U251, U87-MG, and LN-428, as 
      well as their apoptosis and autophagy-mediated through IL-6/JAK2/STAT3 signaling 
      pathway to explore the molecular mechanisms. Methods: In this study, RG-2, U251, 
      U87-MG, and LN-428 cells were treated with 9 mg/ml HUC-MSCs supernatants. Their 
      responses to HUC-MSCs supernatants treatment and the status of STAT3 signaling 
      were analyzed by multiple experimental approaches to elucidate the importance of 
      HUC-MSCs supernatants for GBM. Results: The results demonstrated that after 
      treatment with HUC-MSCs supernatants, in vitro proliferation of RG-2, U251, 
      U87-MG, and LN-428 cells were inhibited, and their sustained growth was also 
      blocked. RG-2, U251, and U87-MG cells showed significant S phase accumulation, 
      while LN-428 cells were blocked in G0/G1 phase. Their migratory invasive 
      capacities were inhibited, and their apoptosis and autophagy ratios were 
      increased. These effects were mediated through the IL-6/JAK2/STAT3 and its 
      downstream signaling pathway. Conclusion: Our data showed that HUC-MSCs 
      supernatants had anti-tumor effects on GBM cells. It inhibited the proliferation, 
      migration, and invasion of GBM cells and promoted their apoptosis. Negative 
      regulation of the IL-6/JAK2/STAT3 signaling pathway enhanced apoptosis and 
      autophagy in tumor cells, thereby improving the therapeutic effect on GBM.
CI  - (c) The author(s).
FAU - Wang, Mingming
AU  - Wang M
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - Zhang, Yufu
AU  - Zhang Y
AD  - Department of Hepatobiliary Surgery, Affiliated Hospital of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - Liu, Min
AU  - Liu M
AD  - Department of Pathology, Affiliated Hospital of Yan'an University, Yan'an 716000, 
      Shaanxi Province, China.
FAU - Jia, Yuna
AU  - Jia Y
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - He, Jing
AU  - He J
AD  - Laboratory of Obstetrics and Gynecology, Affiliated Hospital of Yan'an 
      University, Yan'an, 716000 Shaanxi Province, China.
FAU - Xu, Xiangrong
AU  - Xu X
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - Shi, Haiyan
AU  - Shi H
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - Zhang, Yunqing
AU  - Zhang Y
AD  - Laboratory of Obstetrics and Gynecology, Affiliated Hospital of Yan'an 
      University, Yan'an, 716000 Shaanxi Province, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
FAU - Liu, Yusi
AU  - Liu Y
AD  - Department of Cell Biology and Genetics, Medical College of Yan'an University, 
      Yan'an 716000, Shaanxi Province, China.
LA  - eng
PT  - Journal Article
DEP - 20230227
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC10088538
OTO - NOTNLM
OT  - IL-6/JAK2/STAT3 signaling pathway
OT  - glioblastoma
OT  - human umbilical cord mesenchymal stem cell supernatant
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2023/04/15 06:00
MHDA- 2023/04/15 06:01
PMCR- 2023/01/01
CRDT- 2023/04/14 02:39
PHST- 2022/08/10 00:00 [received]
PHST- 2023/01/17 00:00 [accepted]
PHST- 2023/04/15 06:01 [medline]
PHST- 2023/04/14 02:39 [entrez]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/01/01 00:00 [pmc-release]
AID - jcav14p0611 [pii]
AID - 10.7150/jca.77905 [doi]
PST - epublish
SO  - J Cancer. 2023 Feb 27;14(4):611-627. doi: 10.7150/jca.77905. eCollection 2023.